RASAGILINE (RASAGILINE MESYLATE)

USDailyMed:Rasagiline AU:B3 N04BD02(WHO) AU:S4(Prescription only)BR:Class C1(Other controlled substances)CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-only (R)-N-(prop-2-ynyl)-2,3-dihydro-1H-inden-1-amine 136236-51-6Y 3052776 6641 DB01367Y 2314553Y 003N66TS6T D08469Yas salt:D02562Y ChEMBL887Y RAS (PDBe,RCSB PDB) DTXSID3041112 Interactive image C#CCN[C@H]2c1ccccc1CC2 InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1YKey:RUOKEQAAGRXIBM-GFCCVEGCSA-NY Rasagiline, sold under the brand nameAzilectamong others, is amedicationwhich is used in the treatment ofParkinson's disease.It is used as amonotherapyto treat symptoms in early Parkinson's disease or as anadjunct therapyin more advanced cases.The drug is takenby mouth. Side effectsof rasagiline includeinsomniaandorthostatic hypotension, among others.Rasagiline acts as aninhibitorof theenzymemonoamine oxidase(MAO) and hence is amonoamine oxidase inhibitor(MAOI).More specifically, it is aselectiveinhibitor ofmonoamine oxidase B(MAO-B).The drug is thought to work by increasing levels of themonoamine neurotransmitterdopaminein thebrain.Rasagiline showspharmacologicaldifferences from the related drugselegiline, including having noamphetamine-likemetabolites,monoamine-releasingactivity, ormonoaminergic activity enhanceractions, which may result in clinical differences between the medications. Rasagiline was approved for medical use in theEuropean Unionin 2005and in theUnited Statesin 2006.Generic versionsof rasagiline are available.